Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux
- PMID: 31832877
- DOI: 10.1007/s11255-019-02357-1
Urinary biomarkers of latent inflammation and fibrosis in children with vesicoureteral reflux
Abstract
Purpose: To investigate the urinary levels of TGF-β1, VEGF, and MCP-1 as potential biomarkers of latent inflammation and fibrosis in the kidney before and 6 months after correction of vesicoureteral reflux (VUR) in children.
Methods: A total of 88 patients (mean age 26 months) with VUR were divided into three groups: group A-patients with grades II-III VUR, conservative treatment; group B-patients with grades III-V VUR, endoscopic correction of VUR; group C-patients with grades III-V VUR, ureteral reimplantation after failed endoscopic correction. Control group included 20 healthy children. Biomarker levels were measured by ELISA. 99mTc-DMSA scintigraphy and renal histology were performed if possible.
Results: At admission, TGF-β1 was close to control in all study groups, VEGF increased with severity of the disease, and MCP-1 increased in group C. Six months after correction of VUR, despite clinical and laboratory improvement, TGF-β1 and MCP-1 increased while VEGF decreased compared to the admission values in all groups; no amelioration of renal scarring was detected either by 99mTc-DMSA scintigraphy or renal histology.
Conclusion: The results support our hypothesis that successful correction of VUR is not sufficient to stop or reduce the latent inflammatory and fibrotic processes that have already started in the kidney regardless of the reflux grade and treatment option. Measuring the urinary levels of TGF-β1, VEGF, and MCP-1 may aid in the development of non-invasive, pathophysiologically relevant approach to diagnosis and monitoring of kidney injury and fibrosis in children with VUR.
Keywords: Biomarker; Children; Fibrosis; Nephrosclerosis; Vesicoureteral reflux.
Similar articles
-
Urinary excretion of EGF and MCP-1 in children with vesicoureteral reflux.Int Braz J Urol. 2017 May-Jun;43(3):549-555. doi: 10.1590/S1677-5538.IBJU.2015.0132. Int Braz J Urol. 2017. PMID: 28191787 Free PMC article.
-
How the 99mTc-DMSA scintigraphy findings are reflected in the adopted treatment of primary vesicoureteral reflux: One centre experience.J Pediatr Urol. 2023 Aug;19(4):456-462. doi: 10.1016/j.jpurol.2023.01.017. Epub 2023 Feb 13. J Pediatr Urol. 2023. PMID: 36870928
-
URINARY EXCRETION OF TGF-Β1 AND VEGF IN CHILDREN WITH VESICOURETERAL REFLUX.Wiad Lek. 2020;73(11):2411-2415. Wiad Lek. 2020. PMID: 33454675
-
Contemporary Management of Vesicoureteral Reflux.Eur Urol Focus. 2017 Apr;3(2-3):181-188. doi: 10.1016/j.euf.2017.08.012. Epub 2017 Sep 12. Eur Urol Focus. 2017. PMID: 28918954 Review.
-
Dimercaptosuccinic acid scan challenges in childhood urinary tract infection, vesicoureteral reflux and renal scarring investigation and management.Minerva Urol Nefrol. 2017 Apr;69(2):144-152. doi: 10.23736/S0393-2249.16.02509-1. Epub 2016 Jun 29. Minerva Urol Nefrol. 2017. PMID: 27355216 Review.
Cited by
-
Effect of pneumovesicoscopic cohen surgery with adjustable suspension technique through the urethra on the treatment of primary vesicoureteral reflux disease in infants.BMC Surg. 2023 Apr 28;23(1):105. doi: 10.1186/s12893-023-01996-7. BMC Surg. 2023. PMID: 37118712 Free PMC article.
-
Vesicoureteral Reflux and Innate Immune System: Physiology, Physiopathology, and Clinical Aspects.J Clin Med. 2023 Mar 19;12(6):2380. doi: 10.3390/jcm12062380. J Clin Med. 2023. PMID: 36983379 Free PMC article. Review.
-
Utility of Urinary Biomarkers Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 as a Marker for Diagnosing the Presence of Renal Scar in Children with Vesicoureteral Reflux (VUR): A Cross-Sectional Study.J Indian Assoc Pediatr Surg. 2022 Jan-Feb;27(1):83-90. doi: 10.4103/jiaps.JIAPS_334_20. Epub 2022 Jan 11. J Indian Assoc Pediatr Surg. 2022. PMID: 35261519 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous